These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39329476)

  • 1. Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs.
    Perdrizet J; Wilson M; Wannaadisai W; Apodaca K; Grant L
    Expert Rev Vaccines; 2024; 23(1):879-886. PubMed ID: 39329476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
    Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
    Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
    Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
    Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
    Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
    Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
    Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
    Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
    Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
    Euro Surveill; 2017 Mar; 22(10):. PubMed ID: 28300529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
    Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
    Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
    Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.
    Balsells E; Guillot L; Nair H; Kyaw MH
    PLoS One; 2017; 12(5):e0177113. PubMed ID: 28486544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.